CHMP Backs AbbVie's Rinvoq for Giant Cell Arteritis Treatment in Adults
Key Insights
The European Medicines Agency's CHMP has recommended approval of AbbVie (search)'s Rinvoq (upadacitinib) for treating adult patients with giant cell arteritis (search), marking a potential new treatment option for this rare inflammatory disease.
Rinvoq, a JAK inhibitor, demonstrated significant efficacy in maintaining sustained remission compared to placebo in the Phase III SELECT-GCA clinical trial.
If approved, this will represent an important advancement in GCA treatment, offering patients an alternative to long-term corticosteroid therapy.
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Rinvoq (upadacitinib) for the treatment of adult patients with giant cell arteritis (search) (GCA). This recommendation marks a significant step forward in expanding treatment options for this rare inflammatory blood vessel disease.
Clinical Trial Success Drives Recommendation
The CHMP's positive opinion is based on robust data from the Phase III SELECT-GCA clinical trial, which evaluated the efficacy and safety of Rinvoq in adult patients with GCA. The study demonstrated that Rinvoq, a selective JAK inhibitor, effectively maintained sustained remission while allowing for reduction in corticosteroid use.
"Giant cell arteritis (search) represents a significant burden for patients, often requiring long-term corticosteroid treatment that can lead to serious complications," says Neil Gallagher, M.D., Ph.D., Vice President, Development, AbbVie (search). "This positive CHMP opinion brings us closer to offering patients a new therapeutic option that could help address the challenges of current treatment approaches."
Disease Impact and Treatment Landscape
Giant cell arteritis (search) primarily affects adults over 50, with women being three times more likely to develop the condition than men. The disease causes inflammation in the walls of medium and large arteries, leading to symptoms such as headaches, scalp tenderness, jaw pain, and vision problems. If left untreated, GCA can result in serious complications, including blindness and aortic aneurysm.
Currently, the standard treatment for GCA involves high-dose corticosteroids, which can cause significant side effects when used long-term. The introduction of Rinvoq could provide physicians with an important alternative treatment option that may help reduce reliance on corticosteroids while maintaining disease control.
Mechanism of Action and Clinical Benefits
Rinvoq works by selectively inhibiting JAK1 (search), a key enzyme involved in the inflammatory signaling pathway. This targeted approach helps modulate the immune response that drives GCA pathogenesis. In clinical trials, patients treated with Rinvoq showed significant improvements in achieving and maintaining remission compared to those receiving placebo plus a steroid taper.
The safety profile observed in the SELECT-GCA trial was consistent with the known safety profile of Rinvoq in its approved rheumatic disease indications, with no new safety signals identified.
Regulatory Path Forward
Following this positive CHMP opinion, the European Commission will review the recommendation and make a final decision on marketing authorization in the coming months. If approved, Rinvoq would become an important addition to the treatment arsenal for GCA, potentially benefiting patients across the European Union who struggle with this challenging condition.